Rosetta Genomics Ltd. Announces Continued Listing on NASDAQ

PHILADELPHIA, PA and REHOVOT, ISRAEL--(Marketwire - March 08, 2011) - Rosetta Genomics, Ltd. (NASDAQ: ROSG) today announced that the NASDAQ Listing Qualifications Staff has determined to continue the listing of the Company’s securities on NASDAQ given that the Company satisfied the terms of its February 7, 2011, extension letter by evidencing stockholders’ equity in excess of NASDAQ’s minimum threshold of $2.5 million for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5550(b)(1). NASDAQ will continue to monitor the Company’s periodic reports to confirm the Company’s ongoing compliance with the stockholders’ equity requirement. Separately, the Company must evidence compliance with the minimum $1.00 bid price requirement for continued listing on NASDAQ by August 8, 2011, for a minimum of 10 consecutive business days.

“As a result of our recently announced private placement and concurrent registered offerings and the successful initial public offering in Israel of our majority-owned subsidiary, Rosetta Green, we were successful in increasing stockholder equity beyond NASDAQ’s listing requirement. We are very pleased to have regained compliance with the rule,” said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.

About Rosetta Genomics
Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s microRNA-based tests, miRview™ squamous, miRview™ mets, miRview™ mets(2) and miRview™ meso, are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. To learn more, please visit www.rosettagenomics.com.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the continued listing on the NASDAQ Capital Market constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the “Risk Factors” section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2009 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.